Jiyoung Chae
Primary Care · West Lafayette, INNPI 1568845295
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $903, 3.7 times the $247 reported in 2021. Among primary care clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$353
- Pfizer$332
- Novartis$303
- Otsuka America Pharmaceutical, Inc.$272
- Lilly USA, LLC$254
- Neurocrine Biosciences, Inc.$226
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,035100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $353 |
| Pfizer | 22 | $332 |
| Novartis | 11 | $303 |
| Otsuka America Pharmaceutical, Inc. | 14 | $272 |
| Lilly USA, LLC | 12 | $254 |
| Neurocrine Biosciences, Inc. | 11 | $226 |
| Bayer | 13 | $206 |
| GSK | 11 | $204 |
| E.r. Squibb & Sons, L.L.C. | 9 | $137 |
| Xeris Pharmaceuticals, Inc. | 6 | $99 |
| Eisai Inc. | 5 | $99 |
| AstraZeneca | 6 | $94 |
| Lundbeck LLC | 3 | $81 |
| Sumitomo Pharma America, Inc. | 4 | $68 |
| Astellas Pharma US Inc | 3 | $64 |
| Boehringer Ingelheim | 2 | $44 |
| Corium, LLC | 2 | $36 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Merck | 2 | $29 |
| Boston Scientific | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| CMP Pharma, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
How this compares
$3,035 in reported general payments places this provider in the 90th percentile of 113 primary care providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 55 | $56,735 |
| OzempicSemaglutide | 30 | $54,049 |
| JardianceEmpagliflozin | 39 | $40,974 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $27,077 |
| MyrbetriqMirabegron | 39 | $24,863 |
| JanuviaSitagliptin Phosphate | 24 | $20,668 |
| RybelsusSemaglutide | 11 | $13,535 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $3,137 |
| Mirtazapine | 67 | $2,136 |
| Atorvastatin Calcium | 198 | $1,550 |
| Potassium Chloride | 123 | $1,538 |
| Duloxetine Hcl | 50 | $1,361 |
| Omeprazole | 102 | $1,327 |
| Losartan Potassium | 146 | $1,305 |
| Levothyroxine Sodium | 144 | $1,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $353 | $67,58341 claims |
| PfizerEliquis | $332 | $56,73555 claims |
| Boehringer IngelheimJardiance | $44 | $40,97439 claims |
| GSKTrelegy Ellipta | $204 | $27,07719 claims |
| Astellas Pharma US IncMyrbetriq | $64 | $24,86339 claims |
| MerckJanuvia | $29 | $20,66824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 113 primary care providers in Indiana.
Other primary care in West Lafayette
- Katrina MotleyIndianapolis$18K
- Stephanie BodamerBloomington$6K
- Candace KapranosGary$5K
- Jalyn GoolsbyNew Albany$4K
- Ashley VirtMuncie$4K
- Lana HumeCarmel$3K
- Illia LeiberingTell City$3K
- Leigha Bowyer-JonesJeffersonville$3K
- Heather PickettNoblesville$2K
- Abigail BurkeSheridan$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.